AXS Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

AXS Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,350	Closed	-$564K	–	312
2024 Q1	$564K	Buy	+1,350	New	+$571K	0.14%	213

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AXS Investments's VRTX Position: Q2 2024 in Review

AXS Investments sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 1,350 shares — an estimated $564K sold.

AXS Investments first reported a position in VRTX in Q1 2024 and held it in 1 quarter. The position peaked at $564K in Q1 2024. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

AXS Investments reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
AXS Investments sold 1,350 Vertex Pharmaceuticals shares in Q2 2024, an estimated $564K.
AXS Investments first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 1 quarter.
AXS Investments's Vertex Pharmaceuticals position peaked at $564K in Q1 2024.
1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on AXS Investments's 13F filing for Q2 2024, filed 13 Aug 2024.